What exactly changed in the SION analyst rating on March 02, 2026?

UBS **maintained a Buy** on Sionna Therapeutics (SION) on March 02, 2026. StreetInsider also reported that Guggenheim raised its price target to **$50** after FY25 results, creating mixed but positive signals.

How should investors interpret a maintained Buy in the SION analyst rating?

A maintained Buy means the analyst stays positive but sees no need to change guidance now. Investors should pair the SION analyst rating with catalysts, cash runway, and trial timelines before acting.

Does the SION price target at $50 change the investment case?

A **$50** price target from Guggenheim raises upside expectations, but it is one analyst view. Compare that SION analyst rating and target with fundamentals and risk tolerance.

What is Meyka AI’s current view on Sionna Therapeutics based on this rating?

Meyka AI rates SION **B+**, reflecting analyst sentiment, sector performance, and financial metrics. The SION analyst rating and the $50 target increase upside, but execution risk remains.

Analyst Ratings

UBS Maintains Buy on Sionna Therapeutics, Inc. (SION) March 02, 2026

ByHuzaifa Zahoor March 3, 2026March 3, 2026

UBS maintained a Buy rating on Sionna Therapeutics, Inc. (SION) on March 02, 2026. This SION analyst rating was posted at 11:46 AM and appears alongside StreetInsider coverage that notes Guggenheim raised a price target to $50 after Sionna’s FY25 results. The market reaction was muted with a -0.99% move, or -$0.34, on the update. We review what the SION analyst rating means now, the linked price target moves, and how investors should weigh them.